NASDAQ$CRIS
Curis Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Curis reported a net loss for Q2 2021, but made progress with CA-4948 clinical trials and presented positive data at EHA.
Curis reported a net loss of $10.8 million, or $0.12 per share, for the second quarter of 2021. The company continued to advance its pipeline of cancer therapies, particularly CA-4948, and presented updated clinical data at the European Hematology Association (EHA) Virtual Congress.
- Curis presented positive updated data from Phase 1/2 study of CA-4948 monotherapy in AML and MDS at EHA 2021.
- Clear anticancer activity was observed in molecularly-enriched AML/MDS population with spliceosome or FLT3 mutations.
- Further anticancer activity was also observed in a broader population of AML/MDS patients.
- Curis expects to report additional clinical data by year-end in AML/MDS patients with SF3B1 and U2AF1 spliceosome mutations.
Headline financials
Revenue & EPS history
Curis · Revenue · Quarterly
$2.29M
Revenue by segment
Curis · $2.35M total across 1 segment · Q2 2021
- Royalties$2.35M-4.0%100.0%
Forward guidance
Curis plans to initiate dosing in the combination stage of the Phase 1/2 study of CA-4948 plus azacitidine and CA-4948 plus venetoclax, report additional clinical data from the Phase 1/2 monotherapy study of CA-4948 in AML/MDS patients with spliceosome mutations, and report initial safety data from the ongoing Phase 1 monotherapy study of CI-8993 for the treatment of R/R solid tumors.
Tailwinds
- Initiate dosing in the combination stage of the Phase 1/2 study of CA-4948 plus azacitidine and CA-4948 plus venetoclax in the second half of 2021.
- Report additional clinical data from the Phase 1/2 monotherapy study of CA-4948 in AML/MDS patients with spliceosome mutations by year-end 2021.
- Report initial safety data from the ongoing Phase 1 monotherapy study of CI-8993 for the treatment of R/R solid tumors by year-end 2021.
- Report initial data at a medical meeting from the ongoing Phase 1/2 combination study of CA-4948 plus ibrutinib in patients with B cell cancers in the first half of 2022.
- Existing cash, cash equivalents and investments should enable it to maintain its planned operations into 2024.
Headwinds
- Curis may experience adverse results, delays and/or failures in its drug development programs.
- Curis's drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization.
- Favorable results seen in preclinical studies and early clinical trials of Curis's drug candidates may not be replicated in later trials.
- Curis faces risks relating to the transfer and encumbrance of certain royalty and royalty-related payments on commercial sales of Erivedge.
- Curis faces substantial competition.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2021
-1.7%
Avg return
Earnings day
-1.2%
Avg return
5 days after
+14.9%
Avg return
30 days after
37%
23 / 63 earnings
Positive
+46.2%
Q4 2017
Best reaction
-26.3%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.3% | -4.6% | — | |
| Q1 2026 | -9.5% | -13.1% | -23.7% | |
| Q3 2025 | -7.2% | -15.8% | -7.5% | |
| Q4 2024 | -9.5% | -38.6% | -32.4% | |
| Q3 2024 | +0.5% | -3.6% | -9.2% | |
| Q2 2024 | -8.8% | -12.4% | +0.9% | |
| Q1 2024 | +1.1% | -2.8% | -40.2% | |
| Q4 2023 | +10.9% | +8.0% | +11.8% | |
| Q3 2023 | -3.0% | +15.3% | +151.8% | |
| Q2 2023 | -11.5% | -17.7% | -26.6% | |
| Q1 2023 | -0.6% | +2.5% | +6.2% | |
| Q4 2022 | -10.9% | -14.3% | +31.7% | |
| Q3 2022 | +5.1% | +15.4% | -1.3% | |
| Q2 2022 | +2.0% | +0.0% | -7.1% | |
| Q1 2022 | -12.6% | +2.0% | -6.0% | |
| Q4 2021 | +9.2% | +15.7% | -15.4% | |
| Q3 2021 | -0.7% | -2.5% | -21.1% | |
| Q2 2021 | -6.9% | -10.1% | +13.9% | |
| Q1 2021 | +33.0% | +53.1% | -18.5% | |
| Q4 2020 | -1.7% | +10.2% | +10.8% | |
| Q3 2020 | +12.0% | +13.9% | +647.2% | |
| Q2 2020 | +16.8% | +19.3% | -16.0% | |
| Q1 2020 | -12.0% | -10.5% | +55.8% | |
| Q4 2019 | -7.1% | -4.2% | +9.7% | |
| Q3 2019 | -26.3% | -39.1% | -24.3% | |
| Q2 2019 | -21.3% | -20.9% | -18.3% | |
| Q1 2019 | -1.6% | -11.4% | -22.7% | |
| Q4 2018 | +5.8% | +5.3% | -5.8% | |
| Q3 2018 | +5.5% | -1.8% | -47.2% | |
| Q2 2018 | -9.8% | -12.4% | -12.4% | |
| Q1 2018 | -10.8% | -12.5% | -11.1% | |
| Q4 2017 | +46.2% | +43.9% | -5.3% | |
| Q3 2017 | -11.3% | -18.5% | -44.4% | |
| Q2 2017 | +0.0% | -1.2% | +21.5% | |
| Q1 2017 | -11.7% | -7.9% | -10.7% | |
| Q4 2016 | +16.1% | +12.5% | +2.0% | |
| Q3 2016 | -3.6% | +11.1% | +20.2% | |
| Q2 2016 | -1.7% | +1.1% | -3.4% | |
| Q1 2016 | +7.3% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | -9.7% | — | — | |
| Q1 2015 | +4.6% | — | — | |
| Q4 2014 | +0.3% | — | — | |
| Q3 2014 | -0.8% | — | — | |
| Q2 2014 | -7.8% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +11.4% | — | — | |
| Q3 2013 | -25.2% | — | — | |
| Q2 2013 | +3.0% | — | — | |
| Q1 2013 | -9.4% | — | — | |
| Q4 2012 | -4.0% | — | — | |
| Q3 2012 | -3.4% | — | — | |
| Q2 2012 | -0.9% | — | — | |
| Q1 2011 | +2.9% | — | — | |
| Q1 2012 | +0.6% | — | — | |
| Q4 2011 | -1.9% | — | — | |
| Q3 2011 | -6.8% | — | — | |
| Q3 2010 | -6.8% | — | — | |
| Q2 2011 | -10.6% | — | — | |
| Q2 2010 | -10.6% | — | — | |
| Q4 2010 | +2.4% | — | — | |
| Q1 2010 | -6.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro